Fund moves
19 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 12, 2025 · Filed Nov 12, 2025
A Dexcom director sold $59K of Dexcom shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$58,767
Shares × reported transaction price
13 days after results of Oct 30, 2025, 61 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $59.61 on Nov 12, 2025, 9% above its 52-week low and 34% below its high, after a 10% drop over the previous 30 trading days
52-week range $54.84 (Nov 10, 2025) to $90.75 (Feb 24, 2025), 13% of the way up, from 250 adjusted closes. 30 trading days earlier: $66.08 on Oct 1, 2025. Describes the past only, not a forecast
RSI 40, 23% under its 200-day average, 12% under its 50-day average, 34% below the 52-week high, 20-day volatility 70% a year, against the S&P 500: −13 points over 1 month, −31 points over 3 months, −47 points over 6 months
From the adjusted closes up to Nov 12, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Nov 10, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
5 such cases were open. Oakland County Employees Retirement System v. DexCom, Inc., docket 1:25-cv-09370, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.2% | −2.9% | +0.7% |
| 30 days | +10.1% | +1.3% | +8.8% |
| 90 days | +14.1% | +3.0% | +11.2% |
| 180 days | +2.4% | +9.8% | −7.5% |
| 365 days | +39.5% | +12.3% | +27.3% |
Past results only. Not a forecast.
Fund moves
19 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 1, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Richard Alexander Collins (Director) sold ~$172K of Dexcom
Planned saleFund moves
45 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 17, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.